Legend: 
= Applied Session,
= Theme Session,
= Presenter, Sheraton Seattle Hotel & Towers = “S”
Washington State Convention & Trade Center = “CC”, Grand Hyatt Seattle = “H”
|
|
|
|
|
473
|
Wed, 8/9/06, 2:00 PM - 3:50 PM
|
CC-3A
|
|
Oncology Trials - Contributed - Papers
|
Biopharmaceutical Section, Biometrics Section, ENAR
|
|
Chair(s): David Manner, Eli Lilly and Company
|
|
2:05 PM
|
Evaluating the Quality Reporting of Clinical Trials in Primary Treatment of Brain Tumors —  Lehana Thabane, McMaster University; Rose Lai, Columbia University; Rong R. Rachel, The University of British Columbia; Michael Fraumeni, Juravinski Cancer Centre
|
|
2:20 PM
|
Predicting Malignant Renal Lesions by Using Preoperative Color Doppler Ultrasonography: Building a Nomogram — Alexia Iasonos, Memorial Sloan-Kettering Cancer Center; Ganesh V. Raj, Memorial Sloan-Kettering Cancer Center; Paul Russo, Memorial Sloan-Kettering Cancer Center
|
|
2:35 PM
|
Statistical Properties of a Modified Accelerated Design for Phase I Cancer Clinical Trials — Weili He, Merck & Co., Inc.; Jun Liu, Rutgers University; Hui Quan, sanofi-aventis
|
|
2:50 PM
|
Using Marginal Structural Model To Adjust for Post-Discontinuation Chemotherapy in Cancer Clinical Trials — Yanping Wang, Eli Lilly and Company; Jim Symanowski, Eli Lilly and Company
|
|
3:05 PM
|
On Dose Escalation Rules in Phase I Cancer Clinical Trials — Susan Li, Centocor R&D, Inc.
|
|
3:20 PM
|
Identifying Patients with Newly Diagnosed; Histologically Proven; Untreated; Symptomatic Stage I, II, or III Myeloma Who May Benefit from Dexamethasone — Keyue Ding, Queen's University
|
|
3:35 PM
|
A Statistical Method To Integrate Independent Review and Investigator Review in Clinical Cancer Trial — Xiaolong Luo, Johnson & Johnson Pharmaceutical R&D
|
| |
